Amira JAMOUSSI

Prof. Dr. Amira JAMOUSSI

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AJAmira JAMOUSSI
Amira JAMOUSSI
LMLynda Messaoud
Lynda Messaoud
FJFatma Jarraya
Fatma Jarraya
EREmna Rachdi
Emna Rachdi
NMNacef Ben Mrad
Nacef Ben Mrad
JKJalila Ben Khelil
Jalila Ben Khelil
Objective: The aim of this study is to explore the role of IL6 in predicting outcome in critically ill COVID-19 patients. Design Prospective observational cohort study. Setting 20-bed respiratory medical intensive care unit of Abderrahmen Mami Teaching Hospital between September and December 2020. Methods: We included all critically ill patients diagnosed with COVID-19 managed in ICU. IL6 was measured during the first 24 hours of hospitalization. Results: 71 patients were included with mean age of 64 ± 12 years, gender ratio of 22. Most patients had comorbidities, including hypertension (n = 32, 45%), obesity (n = 32, 45%) and diabetes (n = 29, 41%). Dexamethasone 6 mg twice a day was initiated as treatment for all patients. Thirty patients (42%) needed high flow oxygenation; 59 (83%) underwent non-invasive ventilation for a median duration 2 [1–5] days. Invasive mechanical ventilation was required in 44 (62%) patients with a median initiation delay of 1 [0–4] days. Median ICU length of stay was 11 [7–17] days and overall mortality was 61%. During the first 24 hours, median IL6 was 34.4 [12.5–106] pg/ml. Multivariate analysis shows that IL-6 ≥ 20 pg/ml, CPK < 107 UI/L, AST < 30 UI/L and invasive ventilation requirement are independent risk factors for mortality. Conclusions: IL-6 is a strong mortality predictor among critically ill COVID19 patients. Since IL-6 antagonist agents are costly, this finding may help physicians to consider patients who should benefit from that treatment.

6 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AJAmira JAMOUSSI
Amira JAMOUSSI
SASamia Ayed
Samia Ayed
TMTakoua Merhabene
Takoua Merhabene
HDHamdi Doghri
Hamdi Doghri
JKJalila Ben Khelil
Jalila Ben Khelil
MBMohamed Besbes
Mohamed Besbes
Introduction: Influenza A virus infection is a contagious acute respiratory infection which mostly evolves in an epidemic form, less frequently as pandemic outbreaks. It can take a severe clinical form that needs to be managed in intensive care unit (ICU). The aim of this study was to describe the epidemiological and clinical aspects of influenza A, then to determine independent predictive factors of ICU mortality in Abderrahmen Mami hospital, Ariana, Tunisia. Methods: It was a single-center study, including all hospitalized patients in intensive care, between November 1st, 2009 and October 31st, 2019, with influenza A virus infection. We recorded demographic, clinical and biological data, evolving features; then multivariate analysis of the predictive factors of ICU mortality was realized. Results: During the study period (10 consecutive seasons), 120 patients having severe Influenza A were admitted (Proportion = 2.5%) from all hospitalized patients, with a median age of 48 years and a gender-ratio of 1.14. Among women, 14 were pregnant. Only 7 patients (5.8%) have had seasonal flu vaccine during the year before ICU admission. The median values of the Simplified Acute Physiology Score II, Acute Physiologic and Chronic Health Evaluation II and Sepsis-related Organ Failure Assessment were respectively 26, 10 and 3. Virus strains identified with polymerase chain reaction were H1N1 pdm09 (84.2%) and H3N2 (15.8%). Antiviral therapy was prescribed in 88 (73.3%) patients. A co-infection was recorded in 19 cases: bacterial (n = 17) and aspergillaire (n = 2). An acute respiratory distress syndrome (ARDS) was diagnosed in 82 patients. Non-invasive ventilation (NIV) was conducted for 72 (60%) patients with success in 34 cases. Endotracheal intubation was performed in 59 patients with median duration of invasive mechanical ventilation 8 [3.25–13] days. The most frequent complications were acute kidney injury (n = 50, 41.7%), shock (n = 48, 40%), hospital-acquired infections (n = 46, 38.8%) and thromboembolic events (n = 19, 15.8%). The overall ICU mortality rate was of 31.7% (deceased n = 38). Independent predictive factors of ICU mortality identified were: age above 56 years (OR = 7.417; IC95% [1.474–37.317]; p = 0.015), PaO2/FiO2 ≤ 95 mmHg (OR = 9.078; IC95% [1.636–50.363]; p = 0.012) and lymphocytes count ≤ 1.325 109/L (OR = 10.199; IC95% [1.550–67.101]; p = 0.016). Conclusion: Influenza A in ICU is not uncommon, even in A(H1N1) dominant seasons; its management is highly demanding. It is responsible for considerable morbi-mortality especially in elderly patients.

18 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AJAmira JAMOUSSI
Amira JAMOUSSI
SZSarra Zarrouk
Sarra Zarrouk
EREmna Rachdi
Emna Rachdi
FJFatma Jarraya
Fatma Jarraya
NMNacef Ben Mrad
Nacef Ben Mrad
JKJalila Ben Khelil
Jalila Ben Khelil
We aimed to describe lung ultrasound (LUS) findings in COVID-19 pneumonia and to analyze the association with initial severity and outcome. Prospective cohort study among intensive care unit (ICU) patients in a teaching hospital in Tunisia. A 20-bed respiratory medical intensive care unit of Abderrahmen Mami Teaching Hospital from January to December 2021. We included all COVID-19 pneumonia patients managed in ICU. LUS examination and chest computed tomography (CT), when possible, were performed during the first 24 h of ICU stay. LUS findings were described and association with severity was analysed for trends. During the one-year study period, 311 patients were included with a median age of 58 IQR [47–67] years. ARDS was diagnosed in 307 patients (98.7%). Median initial PaO2/FiO2 was 112 IQR [81–157] mmHg. Median length of stay was 10 IQR [7–14] days and overall mortality was of 45.3%. Median LUS score was 29 IQR [25–32]. LUS score gradients were apico-basal and postero-antero-lateral. There was a significant correlation between ROX index and LUS score with r= -0.146 and p = 0.013. LUS score above 25 was significantly associated with chest CT damage exceeding 75% (NPV = 80.7%). LUS score under 25 was significantly associated with chest CT damage < 50% (NPV = 77.5%). No association was found between the LUS score and mortality or the need for invasive ventilation. In COVID-19 pneumonia, LUS is a good and safe tool for initial severity assessment. LUS score is correlated with ROX index and extent of chest damage on CT scan. However, LUS score does not predict outcome nor need for invasive mechanical ventilation.

1 June 2017 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
Souheil ZayetSouheil Zayet
Souheil Zayet
TMT. Merhabene
T. Merhabene
AJAmira JAMOUSSI
Amira JAMOUSSI
AGA. Ghariani
A. Ghariani
LSL. Slim
L. Slim
MBM. Besbes
M. Besbes

1 October 2026 in The Egyptian Journal of Critical Care Medicine
Verified
Journal Article
Open access
PDF file
EREmna Rachdi
Emna Rachdi
ISIlyes Sallemi
Ilyes Sallemi
NMNacef Ben Mrad
Nacef Ben Mrad
FJFatma Jarraya
Fatma Jarraya
SSSelim Sellaouti
Selim Sellaouti
JKJalila Ben Khelil
Jalila Ben Khelil
Introduction: Awake prone positioning (APP) has been widely used in patients with COVID-19-related acute respiratory distress syndrome (ARDS), but its effectiveness may vary depending on the oxygenation interface. This study aimed to compare the response to APP according to different oxygenation interfaces and to identify predictors of response. Methods: We conducted a prospective observational study including adult patients admitted to the intensive care unit for severe to critical COVID-19, from March to May 2021. APP sessions of at least 30 min were performed within the first 24 h using conventional oxygen therapy (COT), high-flow nasal oxygen (HFNO), and noninvasive ventilation (NIV), applied sequentially when tolerated. Arterial blood gases were measured before and 20 min after each session. Response was defined as an increase of ≥ 20% in the PaO₂/FiO₂ ratio. Results: Fifty-six patients were included. Response rates differed across interfaces: 25.5% under COT, 34.4% under HFNO, and 43.9% under NIV. Responders under COT and HFNO had lower intubation rates ( p = 0.03 and p = 0.01, respectively), and responders under HFNO had shorter hospital stays ( p = 0.018). Mortality was higher among non-responders for all interfaces except NIV ( p = 0.6). Higher body mass index (BMI) was associated with response under COT and HFNO, with ROC analysis identifying a predictive cutoff between 27.3 and 28.3 kg/m². Conclusions: The response to APP differs according to the oxygenation interface. APP response may be associated with improved clinical outcomes, particularly under COT and HFNO. Higher BMI appears to predict a favorable response. These findings should be interpreted cautiously given the observational design and sequential application of interfaces.